B
JNP

Bailard’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Bailard’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-55,000
Closed -$558K – 556
2018
Q1 		$558K Hold
55,000
– – 0.04% 299
2017
Q4 		$267K Buy
+55,000
New +$267K 0.02% 390

Other funds holding JNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bailard's JNP Position: Q2 2018 in Review

Bailard sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q2 2018, closing a stake of 55,000 shares — an estimated $558K sold.

Bailard first reported a position in JNP in Q4 2017 and held it in 2 quarters. The position peaked at $558K in Q1 2018. 48 funds tracked by Wall St. Rank hold JNP as of Q2 2018.

  • Bailard reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Bailard sold 55,000 Juniper Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $558K.
  • Bailard first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Bailard's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $558K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Bailard's 13F filing for Q2 2018, filed 8 Aug 2018.